Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Sponsor
Boehringer Ingelheim
Study ID
NCT05130463
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin/Linagliptin — DRUG
    Participants received Empagliflozin 10mg or 25mg and Linagliptin 5mg (Fixed Dose) Film-coated tablets orally once daily with or without food.

Study Details

The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.

Key Dates

Start date
Mar 22, 2022
Status verified
Aug 2025
Primary completion
Apr 8, 2024
Completion
Jul 8, 2024

Study Design

Enrollment
1,053 participants (actual)

Arms

  • Arm: Patients diagnosed with type 2 diabetes mellitus
    Patients aged 19 years or older, diagnosed with type 2 diabetes mellitus in Korea, who initiated treatment with ESGLITEO® for the first time in accordance with the locally approved label.

Primary Outcome Measure

All Reported Adverse Events Collected From Subjects Taking at Least One Dose of ESGLITEO® [ Time Frame: From first trial drug administration up to 24 weeks. ]

Related coverage on Hipa.ai

Related Studies